Royalty Report: Drugs, Chemicals, Coating – Collection: 372477

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 13

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 13

Primary Industries

  • Drugs
  • Chemicals
  • Coating
  • Medical
  • Device
  • Therapeutic
  • Drug Discovery
  • Molecular
  • Delivery
  • Pharmaceuticals
  • Surgical
  • Cancer
  • Nanoparticles

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 372477

License Grant
Licensor hereby grants to Licensee, for the term of this agreement, an exclusive license (with the right to grant sublicenses) under the Licensed Technology to make and have made (including through use of the Reagent), develop, use, import, offer for sale and sell the Product in the Territory.

Licensor shall grant to Licensee, until the last-to-expire valid patent claim of Enzon Patents, a sole license (with the right to grant sublicenses) under those rights Licensor has to the Enzon Patents, solely to develop, make, have made, use, import, offer for sale and sell in the territory that version of the Product that incorporates Reagent as covalently bonded to the Therapeutic Agent and has a branched backbone structure with two (2) arms and a molecular weight of 40K daltons. Such license shall be subject to the retained rights of Enzon and the Enzon affiliates to practice all the inventions described and claimed in the Enzon Patents for the conduct of research and development (such purposes not including in connection with human clinical trials) of pharmaceutical products that it is developing either itself, with its affiliate, or in conjunction with a third party.

Licensor shall grant to Licensee, for the sole purpose of, and with respect to and only with respect to, the manufacture, use, sale, offer for sale, and importation in the territory of that version of the Product that uses Reagent to covalently bond to the Active Molecule in the Therapeutic Agent and has a branched backbone structure with two (2) arms and a molecular weight of 40K daltons, a non-exclusive license under those rights Licensor has

License Property
US Patent 5,650,234 – Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces

US Patent 5,932,462 – Multiarmed, monofunctional, polymer for coupling to molecules and surfaces

Product shall mean Licensee’s lead compound known as of the Effective Date as El0030, the structure of which is set forth in the agreement and which is, a product produced by linking the Therapeutic Agent to the Reagent by means of Pegylation.

EI0030 is a pegylated aptamer containing 32 monomeric units (32-mer) arranged as a linear sequence of three oligonucleotide segments connected by non-nucleotide hexaethylene glycol spacers. The aptamer terminates in a hexylamino linker to which two 20-kilodalton monomethoxy polyethylene glycol units are covalently attached via the two amino groups on a lysine residue.

Reagent shall mean N-Hydroxysuccinimide ester of bis-(Methoxypoly(ethylene glycol) MW 20,0000)-modified lysine (mPEG2NHS 40K).

Peglation, with correlative meanings “Pegylated” or to “Pegylate”, means covalent chemical bonding of any poly (ethylene glycol) reagent (including the Reagent and including covalent chemical bonding through linking groups) with or to another material or materials. Such materials include, without limitation, proteins, peptides, oligonucleotides, other biomolecules, small molecules, therapeutic agents (including the Therapeutic Agent), diagnostic agents, imaging agents and detectable labels. Additional materials that may be Pegylated include without limitation, polymers, liposomes, films, chemical separation and purification surfaces, solid supports, metal/metal oxide surfaces and other surfaces such as, by way of example but not limitation, those on implanted devices, and equipment, where a poly (ethylene glycol) reagent (including the Reagent) is covalently chemically bonded to one or more reactive molecules on the surface of such device or equipment. “PEGYLATION” shall include the synthesis, derivatization, characterization, and modification of PEG for such purposes, together with the synthesis, derivatization, characterization, and modification of the raw materials and intermediates for the manufacture of poly (ethylene glycol) reagents (including the Reagent) or products (including the PRODUCT) incorporating such poly (ethylene glycol) reagent by means of covalent chemical bonding, and all methods of making and using each and all of the foregoing.

Enzon Patents shall mean (a) all patent applications owned or controlled by Enzon or affiliates that were affiliates of Enzon as of January 7, 2002 (Enzon affiliates) that pertain to Pegylation and that claim the composition, manufacture, or use of the product that (i) have issued on or before January 7, 2002, or (ii) issue from any patent application included in claue (a) of this definition. The Enzon Patents include those listed but not limited.
US Patent 5,643,575 – Non-antigenic branched polymer conjugates

Field of Use
The  license pertains to certain of proprietary PEGylation technology to develop, manufacture and commercialize particular products that use our proprietary PEGylation reagent linked with the active ingredient in Fovista®.

Fovista® is an anti-PDGF agent administered in combination with anti-vascular endothelial growth factor (anti-VEGF) therapy for the treatment of neovascular age-related macular degeneration (or wet AMD).

IPSCIO Record ID: 282931

License Grant
Licensor agrees to grant and hereby grants to Company a worldwide, exclusive, royalty-bearing license, with the right to grant sublicenses, in the Licensor licensed technology solely to use selected Reagent for and to research, develop, make, have made, import, use, offer for sale and sell selected product in the field and in the territory.
License Property
Selected Product means the chemical entity resulting from attachment of the Therapeutic Agent to the Selected Reagent by means of Pegylation, as formulated, packaged and sold in finished form.

Selected Reagent means the Reagent that is selected by the Research Committee pursuant to the Research Program to be attached to the Therapeutic Agent by means of Pegylation.

Therapeutic Agent means human recombinant butyrylcholinesterase (BChE) having the amino acid sequence or having an amino acidsequence with 86% sequence identity to such human BChE sequence or a fragment of such a BChE and in each case which has activity of human recombinant butyrylcholinesterase (BChE).

Reagent means a PEG derivative used in the manufacture of a pharmaceutical or diagnostic product or medical device.

PEG means poly(ethylene) glycol or a derivative thereof.

Pegylation, with correlative meanings 'Pegylated' or to 'Peglate', means covalent chemical bonding of any Reagent (including Selected Reagent and including covalent chemical bonding through linking groups) with or to another material or materials. Such materials include, without limitation, proteins, peptides, oligonucleotides, other biomolecules, small molecules, therapeutic agents (including Therapeutic Agent), diagnostic agents, imaging agents and detectable labels. Additional materials that may be Pegylated include without limitation, polymers, liposomes, films, chemical separation and purification surfaces, solid supports, metal/metal oxide surfaces and other surfaces such as, by way of example but not limitation, those on implanted devices, and equipment, where a Reagent is covalently chemically bonded to one or more reactive molecules on the surface of such device or equipment. 'Pegylation' shall include the synthesis, derivatization, characterization, and modification of PEG for such purposes, together with the synthesis, derivatization, characterization, and modification of the raw materials and intermediates for the manufacture of Reagents (including Selected Reagent) or products (including Selected Product) incorporating such Reagent by means of covalent chemical bonding, and all methods of making and using each and all of the foregoing.

Patent Application means an application for letters patent, including a provisional application, converted provisional application, continuation application, a continued prosecution application, a continuation-in-part application, a divisional application, a re-examination application, and a reissue application (and in each case any foreign counterpart thereto).

Field of Use
Field means the treatment, prevention or diagnosis of human diseases, disorders or conditions (other than Hemophilia A).

IPSCIO Record ID: 237219

License Grant
Licensor grants an exclusive license, with the right to grant sublicenses, under the Licensed Technology to develop, make, have made, use, import, offer for sale and sell the Product in the Territory.

Licensor shall grant a sole license, with the right to grant sublicenses, under those rights Licensor has to the Enzon Patents, solely to develop, make, have made, use, import, offer for sale and sell in the territory that version of the Product that uses Reagent to covalently bond to the active molecule in Licensees-001 Product and has a branched backbone structure with two (2) arms and a molecular weight of 40K daltons.

Licensor shall grant, for the sole purpose of, and with respect to and only with respect to, the manufacture, use, sale, offer for sale, and importation in the territory of that version of the Product that uses Reagent to covalently bond to the active molecule in Licensees-001 and has a branched backbone structure with two (2) arms and a molecular weight of 40K daltons, a non-exclusive license under those rights Licensor has to patents or patent applications ( other than the Enzon Patents) owned or controlled by Enzon or the Enzon affiliates; and all patent claims owned or controlled by Enzon or the Enzon affiliates that are not within the Enzon Patents;  issue from any patent application filed after January 7, 2002; and claim the composition, manufacture, or use of that version of the Product that uses Reagent to covalently bond to the active molecule in Licensees-001 and has a branched backbone structure with two (2} arms and a molecular weight of 40K daltons.

For the Manufacture and Supply of the Reagent Exclusivity, Licensor will manufacture and supply one hundred percent (100%) of Licensees, its affiliates and sublicensees purchase requirements of the Reagent for the manufacturing of the Product.  Licensee, its affiliates and sublicensees will purchase the Reagent exclusively from Licensor for the manufacture of the Product.

The license granted excludes patent claims owned or controlled by Enzon or the Enzon affiliates that claim the composition of matter of an un-pegylated active molecule, methods of making an un-pegylated active molecule, or methods of using an un-pegylated active molecule (other than a claim to a method of pegylating an unpegylated active molecule), even if such active molecule is contained in or is part of the Product.

License Property
Licensed Technology shall mean, collectively, the Licensor patent rights and the Licensor Know-how.   Licensor has certain rights and rights to sublicense under Enzon patents.

PEG shall mean poly (ethylene glycol).  Pegylation / Pegylated, shall mean covalent chemical bonding of polyethylene glycol.

Product shall mean a product produced by linking Licensees-001 to the Reagent.  Licensees-001 is a vascular endothelial growth factor antagonist.

Reagent shall mean N-Hydroxysuccinimide ester of bis-<Methoxypoly(ethylene glycol} MW 20.0000}-modified lysine (mPEG2NHS 40K}.

Technology relates to the pegylation of Macugen that occurs by linking a reagent supplied by Licensor to the active pharmaceutical ingredient.

Field of Use
Macugenâ„¢ (pegaptanib sodium) is developing for the treatment of the wet form of age-related macular degeneration, known as AMD, and for the treatment of diabetic macular edema, known as DME.

IPSCIO Record ID: 372575

License Grant
Licensor grants a separate worldwide license under Licensors Patent Rights and Know-how to make, have made for it, use, import, have imported, offer for sale and sell that Licensed Product.  The license granted for Atherectomy Catheter is non-exclusive.
License Property
Licensor is engaged in biological, chemical and technical research and has developed a body of technology and know-how including reagents, processes and devices.

The patents are Latent Reactive Chemical Patents.

The Licensed Products means each of the separately sold Medical Products.

Medical Products means a catheter that is specifically designed and labeled to excise stenotic, sclerotic materials from the coronary vascular and peripheral vascular systems.

Licensed Products means Medical Products which are surface-treated with photo-reactive polyacrylamide, photo-reactive polyvinylpyrrolidone, tetrabenzoylbenzyl ether or diphotodiquat, latent-reactive crosslinking compounds, or any combination of these photo-reactive reagents.

U.S. Patents
1. METHOD OF IMPROVING THE BIOCOMPATIBILITY OF SOLID SURFACES
U.S. Patent No. 4,973,493

2. BIOCOMPATIBLE COATINGS FOR SOLID SURFACES

U.S. Patent No. 4,979,959
3. PREPARATION OF POLYMERIC SURFACES VIA COVALENTLY ATTACHING POLYMERS
U.S. Patent No. 5,002,582

4. BIOMOLECULE ATTACHMENT TO HYDROPHOBIC SURFACES
U.S. Patent No. 5,217,492

5. METHOD OF BIOMOLECULE ATTACHMENT TO HYDROPHOBIC SURFACES
U.S. Patent No. 5,258,041

6. BIOCOMPATIBLE DEVICE WITH COVALENTLY BONDED BIOCOMPATIBLE AGENT
U.S. Patent No. 5,263,992

7. RESTRAINED MULTIFUNCTIONAL REAGENT FOR SURFACE MODIFICATION
U.S. Patent No. 5,414,075

8. SUBSTRATE SURFACE PREPARATION
U.S. Patent No. 5,512,329

9. PREPARATION OF CROSSLINKED MATRICES CONTAINING COVALENTLY IMMOBILIZED CHEMICAL SPECIES AND UNBOUND RELEASABLE CHEMICAL SPECIES
U.S. Patent No. 5,563,056

10. RESTRAINED MULTIFUNCTIONAL REAGENT FOR SURFACE MODIFICATION
U.S. Patent No. 5,637,460

11. PHOTOACTIV A TABLE WATER SOLUBLE CROSSLINKING AGENTS CONTAINING AN ONIUM GROUP
U.S. Patent No. 5,714,360

Field of Use
The master license agreement is for the right to coat catheters with certain proprietary coating materials.

IPSCIO Record ID: 222533

License Grant
Licensor grants to Licensee, a separate worldwide license under Licensor’s Patent Rights and Know-how to make, have made for it only by a properly sublicensed Manufacturer as set forth herein, use, import, and sell that Licensed Product. The license granted herein is expressly limited to the specific Licensed Products defined herein, and does not include the right to sublicense except as set forth.  All licenses granted by Licensor to Licensee under this Agreement are non-exclusive unless specifically stated otherwise for a particular Licensed Product.
License Property
Licensed Products means each of the separately sold Medical Products that bear a Hemocompatable Coating and a Drug Delivery Coating.

Medical Products means the vessel connector and flow-limiter components of a surgically implanted graft prosthetic system for coupling vascular members in the coronary asculature, such as the vessel connector and flow-limiter components of the devices in the illustrations in U.S. Patent 6,241,764 B1.

6,241,764 – Stented grafts for coupling vascular members

Drug-Delivery Coating means chemical compositions comprised of poly(ethylene-co-vinyl acetate) and poly(butyl methacrylate) components for the purpose of releasing Compounds from the chemical composition.

Hemocompatable Coating means chemical coating compositions that contain one or more of the following components photo-reactive polyvinylpyrrolidone copolymer, nonphoto-reactive polyvinylpyrrolidone, photo-reactive heparin, a crosslinking agent known to the parties as PR04, and a compound for promoting polymer-to-metal adhesion and known to the parties as TL03, for the purpose of providing a hemocompatable surface to the Medical Products.

Licensor U.S. Patents

Hemocompatable Coating formulations

1.

METHOD OF IMPROVING THE BIOCOMPATIBILITY OF SOLID SURFACES
U.S. Patent No. 4,973,493 issued 11/27/1990

2.

BIOCOMPATIBLE COATINGS FOR SOLID SURFACES
U.S. Patent No. 4,979,959 issued 12/25/1990

3.

PREPARATION OF POLYMERIC SURFACES VIA COVALENTLY ATTACHING POLYMERS
U.S. Patent No. 5,002,582 issued 3/26/1991

4.

BIOCOMPATIBLE DEVICE WITH COVALENTLY BONDED BIOCOMPATIBLE AGENT
U.S. Patent No. 5,263,992 issued 11/23/1993

5.

SUBSTRATE SURFACE PREPARATION
U.S. Patent No. 5,512,329 issued 4/30/1996

6.

PHOTOACTIVATABLE CROSS-LINKING AGENTS CONTAINING CHARGED GROUPS FOR WATER SOLUBILITY
U.S. Patent No. 6,077,698 issued 06/20/2000

7.

SURFACE COATING AGENTS
U.S. Patent No. 6,278,018 B1 issued 08/21/2001

8.

SURFACE COATING AGENT
U.S. Patent No. 6,603,040B1 issued 8/05/2003

9.

SILANE COATING COMPOSITION
U.S. Patent No. 6,706,408B2 issued 3/16/2004
Drug-Delivery Coating formulations

1.

BIOACTIVE AGENT RELEASE COATING
U.S. Patent No. 6,214,901B1 issued 04/10/2001

2.

BIOACTIVE AGENT RELEASE COATING
U.S. Patent No. 6,344,035B1 issued 02/05/2002

Field of Use
This agreement pertains to coating on medical related devices such as stent.

IPSCIO Record ID: 328120

License Grant
Licensor hereby grants to Licensee, for the term of this agreement (the term), a worldwide, exclusive, royalty-bearing license, with the right to grant and authorize sublicenses as provided in this agreement, under Licensor’s interest in the Licensor Licensed Technology solely to make, have made, import, use, offer for sale, sell and otherwise exploit selected product in the field and in the territory. For clarity, the foregoing license does not include the right to make or have made selected reagent.
License Property
The proprietary technology is useful for attaching poly(ethylene) glycol-based molecules to pharmaceutical compounds.

U.S. 5,660,234 – Shallow flow wellhead system
U.S. 5,932,462 – Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
U.S. 6,376,604 – Method for the preparation of 1-benzotriazolylcarbonate esters of poly(ethylene glycol)

Field of Use
Field means the treatment, prevention or diagnosis of human diseases or conditions, other than Hemophilia A, by means of a pharmaceutically active substance administered by subcutaneous injection, intramuscular injection or intravenous administration (including by infusion), provided, however, that if an alternative method of administering selected product is utilized, then such alternative method shall be deemed to be included within the field.

IPSCIO Record ID: 367346

License Grant
Licensor grants a worldwide, exclusive license, with the right to grant sublicenses, under the Licensor Licensed Technology to develop, make, have made, import, export, use, sell, offer for sale and have sold potential products and commercial products in the field.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
Licensor has proprietary technology useful for attaching PEG or poly( ethylene) glycol-based molecules to pharmaceutical compounds, and is engaged in the business of performing research in relation to Reagents and Conjugates and manufacturing bulk quantities of Reagents used in the manufacture of pharmaceutical products.

Licensor Core Technology means
— the composition of Reagents, but specifically excluding those Reagents disclosed in the Licensee VWF Patents that are not Licensor Proprietary Reagents on the effective date;
— methods of using Reagents, but specifically excluding those methods disclosed in the Licensee VWF Patents that are not Licensor Proprietary Methods on the effective date;
— methods of making, processing, analyzing or characterizing Reagents (including selected reagents);
— methods of attaching one or more Reagents, including selected reagents, to or associating one or more Reagents, including selected reagents, with or to any therapeutic agent, including a therapeutic agent, but specifically excluding those methods disclosed in the Licensee VWF patents that are not Licensor Proprietary Methods on the effective date;
— methods of directing or controlling the point of attachment of one or more reagents, including selected reagents, to or associating one or more reagents {including selected reagents) with any therapeutic agent (including a therapeutic agent), but specifically excluding such · methods disclosed in the Licensee VWF patents that are not Licensor Proprietary Methods on the effective date;
— the composition of any product (including conjugates, potential products and commercial products) obtained by attaching or associating one or more reagents, including selected reagents, by Pegylation to or with any therapeutic agent (including a therapeutic agent) other than those compositions defined within, that is a Licensee Proprietary Conjugate, or that falls within the scope of jointly owned technology; and
— methods of making, formulating, combining, processing, using, analyzing or characterizing 2 or more reagents (including selected reagents) in combination.

Potential Product means any chemical entity resulting from attachment of any therapeutic agent to a selected reagent by means of Pegylation that is selected by the Research Committee or any product using Pegylation to extend or otherwise improve the half-life of Factor VII or Factor VIII, whether by using Pegylation technology directly with Factor VII or Factor VIII, or by means of the Pegylation of Von Willebrands Factor (e.g., indirectly using Von Willebrands Factor as a carrier for Factor VIII).

Field of Use
The field means Pegylated Von Willebrands Factor, either for use alone for the treatment of Von Willebrands disease or as a carrier for Factor VIII, in the treatment of Hemophilia A, or Pegylated Factor VIII or Pegylated Factor VII for the treatment of Hemophilia A.
Von Willebrand disease (VWD) is a blood disorder in which the blood does not clot properly. Blood contains many proteins that help the blood clot when needed. One of these proteins is called von Willebrand factor (VWF). People with VWD either have a low level of VWF in their blood or the VWF protein doesn’t work the way it should.

IPSCIO Record ID: 2392

License Grant
The Licensee desires to transfer complete ownership of the Licensee Patents from Licensee to Licensor, grant Licensee an exclusive license under the Patents for High Molecular Weight Products under the terms defined herein, and grant Licensee a non-exclusive license under the Patents for super-oxide dismutase.
License Property
Licensee is the owner of the following patents

.  U.S. Patent No. 5,468,478, entitled 'Conjugates of Superoxide Dismutase
   Coupled to High Molecular Weight Polyalkylene Glycols, issued November 21,
   1995;

.  U.S. Patent No. 5,283,317, entitled 'Intermediates for Conjugation of
   Polypeptides With High Molecular Weight Polyalkylene Glycols, issued February
   1, 1994;

.  U.S. Patent No. 5,080,891, entitled 'Conjugates of Superoxide Dismutase
   Coupled to High Molecular Weight Polyalkylene Glycols, issued January 14,
   1992;

.  U.S. Patent No. 5,006,333, entitled 'Conjugates of Superoxide Dismutase
   Coupled to High Molecular Weight Polyalkylene Glycols, issued April 9, 1991.

IPSCIO Record ID: 203456

License Grant
Attached to this settlement agreement, the Licensor grants a worldwide non-exclusive license under Licensors Patent Rights and Know-how to make, have made for it, use, and sell Licensed Products. The license granted herein is expressly limited to the specific Licensed Products defined herein, and does not include the right to sublicense except to an Affiliate.

This license granted for Laser Angioplasty Catheters is non-cancelable by Licensee during the period from the Effective Date through June 30, 2009.

This license granted for Non-Laser Functioning Catheters and Guidewires for use with Licensees Laser Therapy Systems is non-exclusive.

License Property
The licensors patents include, but are not limited to, Method of Improving the Biocompatibility of Solid Surfaces, Surface Coating Agents and Substrate Surface Preparation.

The Licensed Products means Medical Products that are surface-treated with photoreactive polyvinylpyrrolidone copolymer, non-photoreactive polyvinylpyrrolidone, photoreactive polyacrylamide copolymer, one or more of the photoreactive crosslinking agents known to the parties as PR01 and PR04, a compound for promoting polymer-to-metal adhesion known to the parties as TL03, or any combination of these compounds, for the purpose of providing a lubricious surface to the Medical Products.

MEDICAL PRODUCTS-B1 Laser Angioplasty Catheters
The Medical Products means excimer laser angioplasty catheters specifically adapted for coronary and peripheral use. Medical Products includes Licensees chronic total occlusion laser angioplasty catheters.

MEDICAL PRODUCTS-B2 Non-Laser Functioning Catheters and Guidewires for use with Spectranetics Laser Therapy Systems
The Medical Products means the following Licensee-labeled non-laser functioning catheters and guidewires for Licensees laser therapy system that are specifically designed and labeled for use solely with laser angioplasty catheters (I) BIAS sheath, (ii) support catheters, (iii) cardiac lead locking device, and (iv) chronic total occlusion steerwires.  Medical Products does not include catheters for (I) infusion of diagnostic, therapeutic, or embolic agents in the neurovascular region, or (ii) insertion of therapeutic embolic devices in the neurovascular region. Medical Products does not include catheters used to deliver stents of any type.

Field of Use
Licensee designs, manufactures, markets and distributes single-use medical devices used in minimally invasive surgical procedures within the vascular system in conjunction with our proprietary excimer laser system.

IPSCIO Record ID: 260415

License Grant
The University grants for the Term a worldwide license to develop, make, have made, use, sell, offer to sell, lease, and import Licensed Products and to develop and perform Licensed Processes, which the parties acknowledge may result in the identification of discovered products under Universitys rights.

University grants a first option to add Improvement to the Patent Rights, only in the fields for which exclusive rights, for six months after Company has been notified of the existence of each such Improvement.

License Property
The patent rights are for Heparin and Masspec for Field all but Machines;  for Case 9180 for Field Therapeutics;  for Case 9180 Background to enable and only to enable the practice of patent rights Case 9180; and patent rights Heparinase for Field Heparinase.

Patent titles include Solid-and Solution-Phase Synthesis of Heparin and Other Glycosaminoglycans;  
Synthesis of Oligosaccharides in Solution and on the Solid Support;  Linkers for Synthesis of Oligosaccharides on Solid-Support;  Protecting Groups Useful in the Synthesis of Polysaccharides, Natural Products, and Combinatorial Libraries;  Apparatus and Methods for the Automated Synthesis of Oligosaccharides;   Rationally Designed Heparinases Derived from Heparinase I and II;   System and Method for Notating Polymers;  and, Method for Identifying or Characterizing Properties of Polymeric Units.

Field of Use
The Field all but machines shall mean all fields of use except for the Field Sequencing Machines.

The Field Therapeutics shall mean for internal use in the discovery and development of therapeutic compounds;  and,  the clinical testing, manufacture and sale of therapeutic compounds.  This field shall not include the sale of research reagents or of synthesis machines.

The Field Heparinase shall mean all fields of use except for human use of heparinases as therapeutics in pharmaceutical compositions and except for Field Sequencing Machines.

IPSCIO Record ID: 344540

License Grant
University grants a license under the patent rights to
—  develop, make, have made, use, sell, offer to sell, lease, and import Therapeutic Licensed Products and Diagnostic Licensed Products in the Disease Fields;
—  develop, make, have made, use, sell, offer to sell, lease, and import Reagent Licensed Products; and,
—  develop and perform Licensed Processes, unless earlier terminated per the terms of this Agreement.

For the Limited-Term Option to License Improvements Dominated by Patent –
— Subject to any obligations of University to third parties, University grants an exclusive option to add to the Patent Rights of this Agreement Universitys patent rights in inventions conceived and reduced to practice, before June 1, 2010;
— dominated by the Patent Rights licensed under this Agreement on the Effective Date and,
— arising from research performed solely in the laboratory, and,
— directly related to a Fully funded project as of, or within four (4) months of, Companys being provided a copy of the related invention disclosure form by University.

This agreement is exclusive for Therapeutic and Diagnostic products, but may be exclusive or non-exclusive for the Reagent products.

License Property
University is the owner or joint owner of certain Patent Rights relating to
Non-Linear Hydrophilic-Hydrophobic Biopolymers,
Biodegradable Microparticles and Injectable Nanospheres,
Sub 100Nm Biodegradable Polymer Spheres Capable of Releasing Nucleic Acids,
Targeted Delivery of Nano- or Microparticles Using Nucleic Acid Ligands,
Bioadhesive Polymers-Coated Controlled Release Polymer Particles as Efficient Oral Delivery Vehicles for Biopharmaceuticals,
High Throughput Synthesis of Functionalized Materials,
Method ofldentifying Particles with Desired Characteristics from a Library of Particles,
Formulation of Polymeric Particles for Prostate Cancer Targeting,
Multi-Block Co-Polymer for the Development of Functional Particles,
Nanocrystal-Aptamer-Doxorubicin Multifunctional Conjugate System for Cancer Diagnosis and Treatment,
Method of isolating Nucleic Acid Ligands that are Taken up by Cells and Uses Thereof,
Affibodies as a Targeting Ligand in Controlled Drug Delivery Systems,
Receptor Triggered Controlled Drug Delivery Systems to Cross,
Endothelial and/or Epithelial Cell Layers and their Method of Preparation,
Reverse Micelle Nanoprecipitation A Method for Encapsulating Nucleic Acids in Biodegradable Polymers, and, Amphiphilic Compound Assisted Polymeric Particles for Targeted Delivery.

Licensed Products shall mean Reagent, Therapeutic and Diagnostic Licensed Products.

Reagent Licensed Product shall mean any product used primarily as a reagent for research or other non-therapeutic and non-diagnostic purpose that, in whole or in part
– absent the license granted hereunder, would infringe one or more claims of the Patent Rights; or
– is manufactured by using a Licensed Process or that, when used, practices a Licensed Process.

Therapeutic Licensed Product shall mean any therapeutic product except therapeutic or prophylactic vaccines (which are specifically excluded from the definition of Therapeutic Licensed Product), used for a therapeutic purpose that, in whole or in part
– absent the license granted hereunder, would infringe one or more claims of the Patent Rights; or
– is manufactured by using a Licensed Process or that, when used, practices a Licensed Process.

Diagnostic Licensed Product shall mean any product used for a diagnostic purpose that, in whole or in part
– absent the license granted hereunder, would infringe one or more claims of the Patent Rights; or
– is manufactured by using a Licensed Process or that, when used, practices a Licensed Process.

Field of Use
Disease Field shall mean a field specific to a class of diseases. Examples include, but are not limited to cancer;  cardiovascular disease (atherosclerosis, congestive heart failure, etc.); immune/inflammatory disorders (rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, etc.); respiratory diseases (asthma, emphysema, central obstructive pulmonary disease, etc.); central nervous system disorders (Alzheimers disease, Parkinsons, etc.); and metabolic diseases (obesity, diabetes, etc.).

IPSCIO Record ID: 27987

License Grant
The Company grants to Licensee, a separate worldwide license under the Licensor's Patent Rights and Know-how to make, have made for it by a Manufacturer as defined herein, use and sell that Licensed Product.

The license granted under this Attachment is non-exclusive.

License Property
The Company is engaged in biological, chemical and technical research and has developed a body of technology and know-how, including reagents, processes and devices which the parties believe will improve the performance of various products and processes

“Licensed Products” means Medical Products which are surface-treated with photo-reactive polyvinylpyrrolidone, photo-reactive heparin, diphoto diquat (photo-reactive crosslinking compound) or any combination of these photo-reactive reagents.

“Medical Products” means a single-use, temporary (less than 7 days) catheter placed within the vascular system that is designed, labeled and approved (as may be required by appropriate governmental authority prior to sale) for the purpose of in situ heating or cooling of blood. For the avoidance of doubt, such catheters shall not be designed, labeled or approved for the purpose of infusing or delivering any therapeutic or embolic agents or for the delivery or placement of permanently implantable therapeutic devices (including embolic devices), while the distal tip of such catheter resides at or above the common carotid artery. For purposes of this Attachment B1, saline solutions and contrast media (for placement or diagnostic purposes) are not considered therapeutic agents.

U.S. Patents
1.
METHOD OF IMPROVING THE BIOCOMPATIBILITY OF SOLID SURFACES

U.S.
Patent No. 4,973,493 issued 11/27/90

2.
BIOCOMPATIBLE COATINGS FOR SOLID SURFACES

U.S.
Patent No. 4,979,959 issued 12/25/90

3.
PREPARATION OF POLYMERIC SURFACES VIA COVALENTLY ATTACHING POLYMERS

U.S.
Patent No. 5,002,582 issued 3/26/91

4.
BIOMOLECULE ATTACHMENT TO HYDROPHOBIC SURFACES

U.S.
Patent No. 5,217,492 issued 6/8/93

5.
METHOD OF BIOMOLECULE ATTACHMENT TO HYDROPHOBIC SURFACES

U.S.
Patent No. 5,258,041 issued 11/2/93

6.
BIOCOMPATIBLE DEVICE WITH COVALENTLY BONDED BIOCOMPATIBLE AGENT

U.S.
Patent No. 5,263,992 issued 11/23/93

7.
RESTRAINED MULTIFUNCTIONAL REAGENT FOR SURFACE MODIFICATION

U.S.
Patent No. 5,414,075 issued 5/9/95

8.
SUBSTRATE SURFACE PREPARATION

U.S.
Patent No. 5,512,329 issued 4/30/96

9.
PREPARATION OF CROSSLINKED MATRICES CONTAINING COVALENTLY IMMOBILIZED CHEMICAL SPECIES AND UNBOUND RELEASABLE CHEMICAL SPECIES

U.S.
Patent No. 5,563,056 issued 10/08/96

10.
RESTRAINED MULTIFUNCTIONAL REAGENT FOR SURFACE MODIFICATION

U.S.
Patent No. 5,637,460 issued 6/10/97

11.
PHOTOACTIVATABLE WATER SOLUBLE CROSSLINKING AGENTS CONTAINING AN ONIUM GROUP

U.S.
Patent No. 5,714,360 issued 02/03/98

U.S. Patent Applications
1.
VIRUS INACTIVATING COATINGS

Filed 6/7/95
2.
METHOD AND IMPLANTABLE ARTICLE FOR PROMOTING ENDOTHELIALIZATION

Filed 5/26/95

Foreign Patents
1.
IMPROVEMENT OF THE BIOCOMPATIBILITY OF SOLID SURFACES

Canadian Patent No. 1305068, issued 7/14/92
Australian Patent No. 615637, issued 10/16/87
EPO Patent No. 0326579, issued 1/11/95
2.
BIOMOLECULE ATTACHED TO A SOLID SURFACE BY MEANS OF A SPACER AND METHODS OF ATTACHING BIOMOLECULES TO SURFACES

Canadian Patent No. 1335721, issued 5/30/95

Foreign Patent Applications
1.
BIOCOMPATIBLE COATINGS

Filed in Canada, Europe, Japan, Denmark, and Norway
2.
PREPARATION OF POLYMERIC SURFACES

Filed in Canada, Europe, Japan, Denmark, and Norway
3.
IMMOBILIZATION OF CHEMICAL SPECIES IN CROSSLINKED MATRICES

Filed in Canada, Europe, Australia, Japan
4.
IMPROVEMENT OF THE BIOCOMPATIBILITY OF SOLID SURFACES

Filed in Japan
5.
RESTRAINED MULTIFUNCTIONAL REAGENTS FOR SURFACE MODIFICATION

Filed in Canada, Europe, Australia and Japan

IPSCIO Record ID: 172754

License Grant
Licensor grants to Licensee a non-exclusive, royalty-bearing, world-wide license to make, have made, use and sell up to ten (10) Licensed Products.
License Property
Licensed Product(s) means any low molecular weight polyethelyene glycol material used for human therapeutics which, in the course of manufacture, use, or sale would, in the absence of this license, infringe one or more Valid Claims of one or more Licensor Patents.

Polyethylene glycol (PEG) is a polyether compound with many applications from industrial manufacturing to medicine

Licensor Patents

. U.S Patent No. 5,468,478, entitled 'Conjugates of Superoxide Dismutase Coupled to High Molecular Weight Polyalkylene Glycols, issued November 21,   1995.

. U.S Patent No. 5,283,317, entitled 'Intermediates for Conjugation of Polypeptides With High Molecular Weight Polyalkylene Glycols, issued February 1, 1994.

. U.S Patent No. 5,080,891, entitled 'Conjugates of Superoxide Dismutase Coupled to High Molecular Weight Polyalkylene Glycols, issued January 14,   1992.

. U.S Patent No. 5,006,333, entitled 'Conjugates of Superoxide Dismutase   Coupled to High Molecular Weight Polyalkylene Glycols, issued April 9, 1991.

Field of Use
This agreement pertains to the drug industry used for human therapeutics.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.